Intestinal Microflora in Lung Cancer After Chemotherapy
1 other identifier
interventional
41
1 country
1
Brief Summary
Probiotics modulate the gut microflora and immune status in lung cancer who need chemotherapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_1 lung-cancer
Started Sep 2014
Shorter than P25 for phase_1 lung-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2014
CompletedFirst Submitted
Initial submission to the registry
July 14, 2015
CompletedFirst Posted
Study publicly available on registry
May 13, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2016
CompletedMay 23, 2017
May 1, 2017
1.8 years
July 14, 2015
May 21, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Composition of Microorganisms in stool after probiotic intervention
Primary coordination of fecal samples' 16s(%) rDNA will be compared between two groups using Braycurtis distance based Primary coordination analysis(PCoA)
2 months
Secondary Outcomes (2)
Frequency and severity of Adverse effects during Chemotherapy
2 months
The change of immunity and nutrition index
2 months
Study Arms (2)
Probiotic
EXPERIMENTALMicrobial composition using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
Placebo
PLACEBO COMPARATORMicrobiota modulation using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
Interventions
Microbial composition using probiotic
Eligibility Criteria
You may qualify if:
- Patients scheduled for chemotherapy of lung cancer
You may not qualify if:
- Antibiotic, probiotic or prebiotic usage within 1month
- Other malignancy
- History of abdominal surgery
- Pregnant or breast-feeding (for females)
- Impaired liver or renal function
- Diabetes, thyroid disorder, coagulopathy or bleeding disorders, mental disorder
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Gastroenterology,Qilu Hospital,Shandong University
Jinan, Shandong, 250012, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Yanqing Li, MD.PhD.
Qilu Hospital of Shandong University
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Vice president of Qilu Hospital
Study Record Dates
First Submitted
July 14, 2015
First Posted
May 13, 2016
Study Start
September 1, 2014
Primary Completion
July 1, 2016
Study Completion
July 1, 2016
Last Updated
May 23, 2017
Record last verified: 2017-05